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Transforming growth factor-betaConsiderable evidence supports the idea that cytokines are important mediators of pathophysiologic
processes within the central nervous system (CNS). Numerous studies have documented the increased
production of various cytokines in the human CNS in a variety of neurological and neuropsychiatric
disorders. Deciphering cytokine actions in the intact CNS has important implications for our understanding
of the pathogenesis and treatment of these disorders. One approach to address this problem that has been
used widely employs transgenic mice with CNS-targeted production of different cytokines. Transgenic
production of cytokines in the CNS of mice allows not only for the investigation of complex cellular responses
at a localized level in the intact brain but also more closely recapitulates the expression of these mediators as
found in disease states. As discussed in this review, the ﬁndings show that these transgenic animals exhibit
wide-ranging structural and functional deﬁcits that are linked to the development of distinct neuroin-
ﬂammatory responses which are relatively speciﬁc for each cytokine. These cytokine-induced alterations
often recapitulate those found in various human neurological disorders not only underscoring the relevance
of these models but also reinforcing the clinicopathogenetic signiﬁcance of cytokines in diseases of the CNS.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The central nervous system (CNS) of healthy adult mammals is
relatively free of T lymphocytes and other immunological entities.
The presence of the blood–brain barrier (BBB), a paucity of immune
accessory molecules (e.g., MHC class I) and professional antigen-
presenting cells such as dendritic cells, as well as the presence of
soluble mediators that suppress inﬂammatory and immune-mediated
responses have been taken by some to suggest that the CNS is a site of
immune privilege. Nevertheless, it is quite obvious that despite these
barriers and regulatory signals, the development of inﬂammatory
and/or autoimmune responses occur within the CNS compartment
and this can contribute to the pathogenesis of some signiﬁcant
neurological diseases such a multiple sclerosis (MS). There is now
compelling evidence that cytokines have a key role in such
immunoinﬂammatory processes where they may act both as
regulators of immunity and as mediators of altered neuronal and
glial function [1,2].
Cytokines are a large family of soluble and mostly secreted
proteins that are important autocrine or paracrine regulatory
factors in the host response to injury or immunological challenge.
They coordinate diverse functions necessary for host protection and
tissue regeneration after damage. Cytokines are important media-
tors in bidirectional regulatory circuits between the immune61 293515858.
ll rights reserved.system and the CNS. Furthermore, and similar to the periphery,
cytokines are also multifunctional effectors that target a variety of
different cell types (“pleiotropic”) within the CNS. Production of
cytokines within the CNS may arise from multiple sources
including inﬁltrating leukocytes such as T cells and macrophages
and also from resident neural cells, particularly astrocytes and
microglia. The ability of these glial cells to produce a variety of
cytokines, including IL-1α/β, IL-6, IL-10, IL-12, IFN-α, TNF-α, and
TGF-β [1,3], highlights the possible existence of a cytokine network
within the CNS that is analogous to that of the immune system.
Within this network, cytokines may inﬂuence the production of
each other, either in a stimulatory (e.g., IL-1 and TNF-α can induce
each other as well as IL-6) or inhibitory fashion (e.g., TGF-β or IL-
10 can signiﬁcantly antagonize the production of the proinﬂam-
matory cytokines). Moreover, at a functional level, the actions of
individual cytokines can often overlap with, as well as be unique
from other cytokines, while it is also common for different
cytokines to interact with each other being either synergistic or
antagonistic.
Not surprisingly given the potential for such a marked biological
impact, the cellular production of most cytokines in the CNS, as in
other organs, is normally tightly regulated andmaintained at very low
or negligible levels. However, in many different pathologic states, the
local production of cytokines is increased signiﬁcantly in the CNS.
These mediators are implicated in the pathogenesis of a variety of
neurological disorders (for reviews, see [1,2,4]) such as multiple
sclerosis (MS), subacute sclerosing panencephalitis (SSPE), HIV-
associated dementia (HAD), Alzheimer's disease (AD), spongiform
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and stroke. Due to the complexity of cytokine regulation and actions
whether these factors are causative in human disease or associated
with beneﬁcial or detrimental outcomes and their mechanisms of
action are issues of considerable importance to clarify. The study of
the pathogenesis of neurological disease in humans is clearly limited
and on thewhole has been restricted to postmortem tissuewhichmay
not exhibit pivotal processes that were active and contributed to
lesion initiation and development. Furthermore, although with this
type of approach the knowledge gained has been informative it still
suffers from being largely descriptive, telling us little as to whether a
particular response or factor is primary or secondary, pathogenic or
protective. Therefore, much research in this arena is dependent on
reliable animal models for studying speciﬁc hypotheses related to
human disease processes. The use of genetically manipulated mouse
models in which the expression of speciﬁc cytokine genes is targeted
to the CNS offers one approach to generating answers to some of the
questions posed above. In this review article we discuss these so-
called transgenic models in relation to the CNS-directed production of
some speciﬁc cytokines, highlighting the utility of these models for
understanding the functions of cytokines in the CNS and what these
models tell us about the potential role of these mediators in human
neurological diseases.
2. The multifaceted actions of IL-6 in the CNS
IL-6 belongs to a family of related cytokines that include IL-11, IL-
27, leukaemia inhibitory factor (LIF), oncostatin M, and ciliary
neurotropic factor (CNTF). The receptors for these cytokines have
the shared feature of associating with the integral membrane
glycoprotein gp130. In general, these cytokines are recognized for
their involvement in diverse functions in host defense, bone, muscle,
and cardiovascular function (reviewed in [5]). In relation to the CNS,
members of this cytokine family are known to have important
signaling functions in the normal developing and adult brain and in
the response to brain injury and disease [6]. IL-6 is the founding
member of the gp130 family and was initially discovered as a factor
that induced the differentiation of B cells. However, with time, it has
become abundantly clear that IL-6 inﬂuences a broad range of
biological processes in many different tissues (reviewed in [7]).
The functions of IL-6 are mediated by well-deﬁned signal
transduction pathways [8,9]. Binding of IL-6 to the IL6R induces
gp130 homodimerization with activation of bound tyrosine kinases of
the JAK family that then phosphorylate multiple, highly conserved
tyrosine (Y) residues located on the cytoplasmic domains of gp130.
This in turn triggers the recruitment of STAT1, STAT3, and SHP2
phosphatase which bind to speciﬁc phosphotyrosine sites on
gp130. STAT3 and, to a lesser extent, STAT1, undergo JAK-mediated
phosphorylation on a single tyrosine residue, dissociate from the
receptor and form homo- and heterodimers that translocate to the
nucleus whereupon they bind to speciﬁc DNA recognition motifs in
target genes regulating transcriptional activity. JAK-mediated phos-
phorylation of SHP2 results in the activation of the Ras-ERK1/2/MAPK
cascade. The coordinate activity of the JAK/STAT and SHP2/MAPK
pathways determines the nature of the cellular response to IL-6.
IL-6 likely plays the role of an important mediator of communica-
tion between the periphery and the CNS during inﬂammation [10].
However, IL-6 is also produced locally in the brain and has been
implicated in the pathogenesis of a number of progressive neuroin-
ﬂammatory disorders (reviewed in [11,12]) including MS, AD, viral
and bacterial meningitis, HAD, and stroke. Numerous experimental
studies point to complex effects of IL-6 in the CNS ranging from
increased cellular survival and neuroprotection to the induction of
neuroinﬂammation and subsequent neurodegeneration [11,12].
IL-6 may well have been the ﬁrst cytokine whose gene expression
was targeted speciﬁcally to the CNS in mice using a transgenicapproach [13]. In this transgenic model, expression of a murine IL-6
cDNAwas targeted to astrocytes using amurine GFAP genomic vector.
The astrocyte is a relevant cellular target since, as stated above, these
cells are known to produce IL-6 in response to different stimuli.
Expression of the transgene-encoded IL-6 gene was localized to
astrocytes predominantly in subcortical regions such as the thalamus,
the cerebellum, and the brain stem, with the highest expression
occurring in the Bergmann glia of the cerebellum. Production of
bioactive IL-6 and IL-6 protein can also be found in astrocyte cultures
and lysates of cerebellum derived from the GFAP-IL6 mice. Further-
more, the level of transgene-encoded IL-6 mRNA in the CNS of these
transgenic mice is similar to that found in EAE and thus falls within a
pathophysiological range [14]. Notwithstanding the chronic nature of
the production of IL-6 in the brain of these GFAP-IL6 mice, this model
has proven to be valuable tool in which to study the actions of IL-6.
Neurobehavioral, neuroendocrine, and neurophysiological testing
in the GFAP-IL6 animals highlights signiﬁcant abnormalities in brain
function that correlate with the transgene dose and age of these
animals. Thus, GFAP-IL6 mice exhibit a progressive age-related
decline in avoidance learning performance [15]. In humans, plasma
IL-6 levels increase with age and correlate with cognitive decline [16].
Studies in the GFAP-IL6 mice provided the ﬁrst evidence that local
production of IL-6 in the brain might be causative for the age-related
decline in learning and cognitive function. Proinﬂammatory cytokines
such as IL-6 also may be key modulators of the hypothalamic–
pituitary–adrenal (HPA) axis [17]. Hypothalamic–pituitary–adrenal
function in the GFAP-IL6 mice is perturbed, and while these animals
have normal basal plasma corticosterone levels, following restraint
stress, levels of this stress hormone increase markedly and well above
those in wild type animals [18]. The increased corticosterone levels in
the transgenic mice correlate with increased plasma arginine
vasopressin (AVP) but not ACTH levels suggesting a role for AVP in
the manifestation of this response. A similar mechanism may play a
role in the blunted ACTH response and elevated corticosterone levels
under pathophysiological conditions observed in humans with high
brain levels of IL-6. The HPA axis in humans chronically treated with
IL-6 [19] and in patients with various disorders associated with
elevated IL-6 levels in the brain and cerebrospinal ﬂuid, including AD,
MS, and depression [20,21], exhibit a blunting of ACTH but not cortisol
responses, and the diminished ACTH responses resemble those during
chronic stress [22].
As noted above, GFAP-IL6 mice with high IL-6 production in the
brain exhibit spontaneous seizures. Interestingly, while GFAP-IL6
mice with low production of IL-6 do not have spontaneous seizures,
these animals develop severe tonic–clonic seizures and die following
injection of the glutamatergic excitotoxin kainic acid, at doses that
produce little or no behavioral changes in wild type mice [23]. The
seizure prone phenotype of the GFAP-IL6 mice is reﬂected by overt
hippocampal excitatory pathophysiologywhich appears to be due to a
loss of inhibitory control [24]. Additionally, in hippocampal slices
from GFAP-IL6 mice long-term potentiation in the dentate is
signiﬁcantly reduced in comparison with WT animals [25]. Such
disruption of long-term potentiation and the suppression of theta
rhythm might be indicative of impaired hippocampal synaptic
plasticity and could underlie the altered cognitive function observed
in these transgenic mice.
A number of neurodegenerative changes are seen in the brain of
the GFAP-IL6 mice that have been linked to the functional impair-
ments noted above. In the hippocampus, dendritic vacuolization,
stripping of dendritic spines, decreased synaptic density, and
signiﬁcantly decreased numbers of parvalbumin and calbindin
immunoreactive neurons is observed [13,15]. These degenerative
neuronal changes likely contribute to the hippocampal pathophysiol-
ogy and learning deﬁcits seen in the GFAP-IL6 mice. For example, the
parvalbumin- and calbindin-containing neurons are known to be a
major source of the inhibitory neurotransmitter GABA [26]. Loss or
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inhibitory regulation in the hippocampus and increased excitatory
activity as seen in the EEG recordings from the GFAP-IL6 mice.
Prominent neurodegenerative disease can also be found in the
cerebellum with progressive atrophy and loss of molecular and
granular layer neurons (Fig. 1B). In addition, spongiosis and marked
axonal dystrophy with consequent secondary demyelination are
prevalent throughout the cerebellum [13,27]. These degenerative
changes in the cerebellum likely underlie the motor abnormalities
that occur in older GFAP-IL6 mice.
IL-6 is an important mediator in the immune system and is
involved in the pathogenesis of autoimmune disease [28]. Not
surprisingly the chronic production of low levels of IL-6 in the brain
of the GFAP-IL6 mice induces a progressive neuroinﬂammatory
state. Discrete perivascular accumulation of mononuclear cells can
be found around some larger vessels in the cerebellar sulci and
brain stem [13]. Phenotypically, these perivascular mononuclear
cells are made up of predominantly B220+ B cells and/or plasmaFig. 1. Phenotypic changes in the brain of GFAP-IL6 mice. (A) Intravascular Evans blue dye p
mice. (B) Histological features of the cerebellum of the GFAP-IL6 mice include the presence
neurodegeneration affecting the Purkinje cell and granule cell neuron layers of the cerebellu
(purple) and GFAP (red; left and middle panels) and Iba-1 (red; right panel). Note strong ncells with smaller numbers of CD4+ T cells. The relative contribu-
tion of these immune cells to the degenerative neuropathology is
unclear and remains to be determined. In association with the
neurodegenerative changes, GFAP-IL6 mice were found to have a
diffuse nonproliferative gliosis with marked activation of astrocytes
and microglia [13,29]. Signiﬁcantly, the level of activation of the
microglia associates closely with the degree of neurodegeneration
and learning impairment in the GFAP-IL6 mice [15]. How micro-
gliosis might contribute to the development of neurodegeneration
in these mice is unknown but conceivably could involve production
of an array of inﬂammatory molecules that, together with IL-6,
might mediate neuronal injury. In support of this, evidence has
been obtained at the molecular level for cerebral activation of some
of these inﬂammatory functions and includes the upregulation of
the genes for the acute-phase response factors α1-antichymotryp-
sin, complement C3, and metallothionein I+II, expression of other
cytokine genes including IL-1α, IL-1β, and TNF-α [13,30,31]. In
addition to the glia, marked changes occur to the cerebrovascularerfusion showing BBB leakage in the cerebellum of 3-month-old GFAP-IL6 but not WT
of increased number and more dilated blood vessels revealed by laminin staining and
m as seen by H&E staining. (C) Dual-label immunohistochemical staining for pY-STAT3
uclear staining for pY-STAT3 (arrows) in GFAP-IL6 but not WT specimens.
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progressive proliferative angiopathy in the cerebellum and asso-
ciated breakdown of the blood–brain barrier (BBB) [13,32] (see also
Fig. 1A and B). The failure of the BBB is linked to the endothelial
cells not forming typical tight junctions and the maintenance of
fenestrated endothelium. It is likely that this is due to the chronic
proliferative state of these cells. Surprisingly, despite the gross loss
of BBB integrity, the histogenesis of the cerebellum occurs normally
[32]. Additional changes reﬂecting the chronic inﬂammatory state
include dilation of the vessels and associated increases in a variety
of vascular adhesion molecules and von Willebrand factor [13,33].
In all, it is clear from the preceding that, in the CNS, the glial cells
and the vascular endothelium are major responder cells to IL-6. In
support of this nuclear accumulation of the key IL-6/gp130 signal
transduction molecule, phosphotyrosine (pY)-STAT3 occurs predo-
minantly in astrocytes (Fig. 1C), microglia (Fig. 1C) and the vascular
endothelial cells in the brain of GFAP-IL6 mice [34]. Changes to the
function of these cells induced by IL-6 may therefore be a major
mechanism that establishes the proinﬂammatory milieu of the brain
and the resulting neurodegenerative phenotype.
Although the preceding discussion highlights strong, largely
localized, proinﬂammatory, and neurodegenerative changes caused
by transgene-encoded IL-6 production in the CNS, studies of acute
traumatic brain injury (TBI) in the GFAP-IL6 mice support a major
neuroprotective function of this cytokine. A number of studies
reached the same conclusion that cryolesion-induced injury in the
cortex is reduced signiﬁcantly in the GFAP-IL6 mice [35–37]. The
basis for this protection may well be multifactorial and involve the
proangiogenic effects of IL-6 resulting in more rapid revasculariza-
tion of the injury site [37] and decreased oxidative stress and
apoptotic cell death associated with induction of protective
antioxidant molecules such as metallothionein I+II and the
induction of antiapoptotic genes [35,36]. Intracerebral levels of IL-
6 increase markedly in humans after TBI [38]. While the role of IL-6
in human TBI remains controversial, there are reports of an
association between increased IL-6 and improved neurological
outcome in TBI patients [39,40]. The studies in GFAP-IL6 mice
potentially offer some insight into the molecular and cellular
mechanisms that might underlie any neuroprotective effects
exerted by IL-6 in human TBI.
Much evidence indicates that IL-6 has a major role in the
pathogenesis of a number of experimental and human autoimmune
diseases including MS [41]. IL-6 in combination with TGF-β drives
the development of autoreactive CD4+ Th17 T cells that are major
effector cells in various experimental autoimmune disease models
[42–44]. However, IL-6 produced locally by the target tissue may
also have a signiﬁcant modulatory role in the development of
autoimmunity [45,46]. The GFAP-IL6 model has been used to
examine the induction and evolution of an autoimmune response
in a target tissue in which the microenvironment produces and is
modiﬁed by IL-6. Myelin oligodendrocyte glycoprotein (MOG)
immunization-induced EAE in GFAP-IL6 mice in which production
of IL-6 is restricted to the cerebellum causes an atypical disease
presenting as severe ataxia without the physical signs of spinal cord
involvement and ascending paralysis characteristic of classical
MOG–EAE [47]. Surprisingly, immune pathology and demyelination
are almost completely absent from the spinal cord of MOG-
immunized GFAP-IL6 mice while cerebellar immune pathology
and tissue damage is markedly increased. These studies show that
the local tissue production of IL-6 can target and enhance the
inﬂammatory response directed against an autoantigen. Moreover,
in the case of the GFAP-IL6 mice with EAE, the IL-6 primed
cerebellum seems to generate a leukocyte “sink” that diverts
trafﬁcking and inﬂammation away from the normally dominant
antigenic site of the spinal cord. The mechanisms underlying this
process remain to be determined but likely include the preexistingproduction of speciﬁc cytokines and chemokines as well as the
increased vascular activation and loss of integrity of the BBB in the
cerebellum.
3. Tumor necrosis factor is a mediator of
meningoencephalomyelitis and demyelinating disease
Like IL-6, tumor necrosis factor (TNF) is a plurifunctional cytokine
involved inmany facets of immune system development and function.
TNF belongs to a large family of cytokines that in addition to TNF,
includes lymphotoxin (LT)-α, LT-β, and CD40 (reviewed in [48]).
Studies of these cytokines in the CNS and their role in neuroin-
ﬂammation have been limited somewhat to TNF. TNF is produced by a
variety of cell types and is synthesized in large amounts by activated
macrophage/microglia. There are two biologically active forms of TNF,
a 26-kDa transmembrane precursor, which is a major player in local
cellular interactions and responses [49], and a 17-kDa secreted form,
which is derived from the former by proteolytic enzyme cleavage.
Soluble TNF plays an important role both locally and systematically
[50]. TNF binds to two high-afﬁnity receptors termed TNFRp55 and
TNFRp75 that are coexpressed in most tissues including the CNS [51].
Many studies have demonstrated that TNF is important in a variety of
inﬂammatory disorders including those of the CNS as exempliﬁed by
bacterial meningitis, HAD, cerebral malaria, cerebral ischemia, andMS
(reviewed in [51]).
The relative signiﬁcance of TNF in the pathogenesis of inﬂam-
matory CNS disease has been extensively evaluated using transgenic
modelling with a variety of different transgene constructs that
result in production of different forms of TNF in different cell types
within the brain. These included a murine TNF transgene controlled
by its own promoter [52] that was apparently expressed in glial
progenitor cells [53], a human wild type or transmembrane TNF
expressed in astrocytes or neurons [54], and a murine TNF gene
targeted to astrocytes using the GFAP promoter [55]. In all cases,
with the exception of human transmembrane TNF produced by
neurons, these different transgenic mice develop severe, progressive
motor impairment, paralysis, and cachexia leading to premature
death. This clinical phenotype is accompanied by extensive
meningoencephalomyelitis with widespread accumulation of leuko-
cytes in the brain. In GFAP-MuTNF mice, large numbers of B cells,
CD4+ and CD8+ T cells accumulate at predominantly perivascular
sites while parenchymal lesions contain mostly CD45+ high, MHC
class II+, and Mac-1+ cells of the macrophage lineage with lower
numbers of neutrophils and few CD4+ and CD8+ T cells [55]. In
these latter GFAP-MuTNF mice, the development of primary and
secondary demyelination and neurodegeneration follows the onset
of the immunoinﬂammatory response in the brain. These ﬁndings
suggest that the cellular injury and degeneration in this model are
due primarily to TNF-induced inﬂammation rather than direct toxic
actions of the cytokine. On the other hand, in transgenic mice
expressing murine TNF in glial progenitor cells, myelin vacuolation,
and oligodendrocyte apoptosis are present prior to BBB breakdown
and immune cell inﬁltration in the CNS [53]. Thus, it is likely that
some pathogenic effects of TNF in the CNS depend upon the context
of its expression with both the cellular location and the time of
production being key factors. This latter idea is further reinforced by
the observation that mice producing human transmembrane TNF in
astrocytes develop severe immunoinﬂammatory disease of the CNS
while mice producing the same transmembrane form of TNF in
neurons do not [54].
The primary effect of TNF when expressed as a transgene product
in the brain appears to be to stimulate the recruitment and
trafﬁcking of immunoinﬂammatory cells into the CNS. This process
is likely facilitated by the pronounced activation of the cerebrovas-
cular endothelium that occurs prior to immune cell inﬁltration [55].
However, unlike GFAP-IL12 mice (see below), the majority of
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relatively nonactivated state and do not produce IFN-γ. Therefore,
although TNF production in these transgenic mice promotes the
robust recruitment of T and B cells to the CNS, these cells do not
appear to be pathogenic. In fact, in GFAP-MuTNF mice crossed with
SCID mice, which lack T and B cells, neurological disease is
exacerbated with earlier onset of motor impairment and more
extensive inﬂammatory lesions [55]. The lesions in the CNS of these
immunodeﬁcient GFAP-MuTNF mice are dominated by highly
activated macrophage/microglia. Thus, there is a central role of
macrophage/microglia in mediating destructive inﬂammatory dis-
ease in the CNS in response to TNF. A similar conclusion was reached
from studies of EAE in a transgenic mouse model with oligoden-
drocyte-targeted production of TNF [56]. These mice do not develop
spontaneous neurological disease, however, following induction of
EAE, a more persistent disease with markedly increased macro-
phage/microglial reactivity is seen.
The TNF transgenic mice offer a useful tool to dissect out
the relative functions of the TNFRp55 and TNRp75 receptors
in mediating the actions of TNF in the CNS. A crucial role for
TNFRp55 signaling in both inﬂammation and demyelination is
demonstrated by the ﬁnding that disease is completely abrogated
in transgenic mice producing soluble MuTNF in glial progenitor
cells [53]. Conversely, in this same model, inﬂammatory demye-
linating disease is unaltered by the absence of TNFRp75 indicating
that this receptor does not contribute to pathogenic signaling
by TNF in these mice. However, TNFRp75 signaling does appear
to contribute to immune pathology in the CNS when human
transmembrane TNF is targeted to astrocytes in transgenic mice
in which the human TNFRp75 is overexpressed in the absence of
MuTNFRp55 [57]. In this complex model system, transmembrane
TNF/TNFRp75 interactions cause endothelial cell activation and
the upregulation of adhesion molecules, with the development of
chronic inﬂammation but no oligodendrocyte apoptosis or demye-
lination. The severity of this disease process is increased and its
onset occurs earlier when TNFRp55 is introduced back into the
CNS, indicating there is co-operation between the two receptors in
mediating the effects of the transmembrane TNF. In all, the results
of these studies highlight a proinﬂammatory role for TNFRp75
when signaling alone in the CNS and point to an exclusive role for
TNFRp55 in TNF-mediated oligodendrocyte apoptosis and primary
demyelination.
4. Interleukin-12 (IL-12) stimulates type I, cell-mediated
immunity in the CNS
Interleukin-12 is a heterodimeric cytokine consisting of a p35 and
a p40 subunit that has a pivotal role in innate and adaptive immunity
(reviewed in [58]). IL-12 is produced by macrophages, dendritic cells,
and B cells and has the primary function of promoting type I cellular
immune responses. The IL-12 receptor is a heterodimer consisting of
an alpha and a beta subunit that, following binding of IL-12, initiates
signal transduction via the JAK/STAT pathway resulting in activation
of STAT4. Consistent with its function as a key mediator of cellular
immunity, IL-12 stimulates naive and activated CD4+ and CD8+ T
cells as well as NK cells. This stimulation leads to increased
proliferation, activity, and, most importantly, induces the production
of IFN-γ in T and NK cells which is a key signature of a T helper 1 (Th1)
response. The immune response of mice andmen against intracellular
parasites such as Leishmania and Toxoplasma gondii, bacteria, viruses,
tumors, transplanted tissue, and autoimmune disorders relies heavily
on the actions of IL-12.
In the brain, IL-12 has been observed in the course of
endotoxemia in mice and in MS lesions of humans [59–61]. The
cellular source of IL-12 in the CNS include microglia [59,60,62] and
astrocytes [60,63]. Studies of EAE [64] and a recent clinical trial inMS [65] found that genetic loss and neutralization of IL-12,
respectively, do not alter the development or progression of
disease, suggesting that IL-12 does not play a crucial role in the
pathogenesis of these autoimmune diseases. The strong induction
of IL-12 in the brain mediated by LPS suggests that a key role of
this cytokine may be in antimicrobial defense [59,60]. In support of
this, endogenous IL-12 is required for the long-term maintenance
of IFN-γ-dependent resistance against intracellular pathogens such
as T. gondii and that absence of IL-12 results in a lethal encephalitis
[66].
In order to further evaluate the functions of IL-12 in the CNS,
transgenic mice that produce IL-12 under the transcriptional control
of the GFAP promotor were established [67]. This was accomplished
by the simultaneous microinjection into the germ line of a GFAP-
IL12p40 and a GFAP-IL12p35 transgene. At an age of 4–6 months,
low-expressor GFAP-IL12 transgenic mice spontaneously develop
adverse clinical signs characterized by progressive ataxia, dimin-
ished body weight, and muscle atrophy. In contrast to the GFAP-
IL12 mice, transgenic mice that produce only the p40 subunit of IL-
12 in the brain do not develop neurological disease. Histologically,
severe immunoinﬂammatory lesions localized predominantly to
areas of highest IL-12 production in the cerebellum and the
overlying meninges occur in the brain of diseased GFAP-IL12 mice
(Fig. 2). These lesions contain large numbers of CD4+ and CD8+ T
and NK cells as well as numerous calcium deposits. The inﬁltrating T
cells present in the lesions have an activated phenotype and
produce high amounts of IFN-γ, IL-1, and TNF indicating a type 1
(cell-mediated) immune response in the CNS. The meningioence-
phalitis ﬁndings resemble the human disorders MS and viral or
chronic bacterial encephalitis. The calcium deposits on the other
hand are not a usual ﬁnding in adults with these neurological
disorders.
The development of disease in the GFAP-IL12 mice depends on
the presence of lymphocytes and IFN-γ, respectively. Thus, GFAP-
IL12 mice with a homozygous disruption of either the RAG2 gene or
the IFN-γ gene do not develop neurological disease [68]. These
ﬁndings demonstrate that lymphocyte entry into the CNS is the
pivotal event in the pathogenesis of neurological disease in the
GFAP-IL12 mice. Lymphocytes that enter the brain in transgenic
mice are stimulated by IL-12 and are induced to produce IFN-γ. The
latter in turn leads to the induction of the plethora of interferon-
induced genes in CNS resident as well as in immune cells that have
a multitude of effects such as upregulation of transgene expression
via reactive astrocytosis and upregulation of adhesion molecules
on endothelial cells that leads to the enhanced recruitment of
lymphocytes to the brain. Thus, a vicious cycle occurs which drives -
IL-12 production, lymphocyte entry into the CNS and IFN-γ
production. CNS resident cells are not the major targets of IL-12
since the brain is unaffected in GFAP-IL12 mice that lack
lymphocytes and/or IFN-γ. It is likely that CNS resident cells lack
surface expression of either or both IL-12 receptor subunits and are
therefore unresponsive to IL-12.
Immunization of young GFAP-IL12 mice with complete Freund's
adjuvant without a speciﬁc CNS antigen induces earlier onset and
more severe disease [69]. The changes in the CFA-stimulated GFAP-
IL12 mice reproduces the spontaneous disease that develops in this
line thereby underlining the notion that the spontaneous disease
might be triggered by intercurrent peripheral immune stimuli that
need not be speciﬁc for the CNS. The trafﬁcking of lymphocytes
into the brain is modulated by the immune status of the host and
is increased during peripheral immune challenge [70,71]. In
addition, expression of the IL-12 receptor is known to accompany
the transition of T cells from a naïve to primed state [72,73].
Peripheral immunization of the GFAP-IL12 mice most likely leads
to an increase in the number of IL-12 receptor bearing T cells that
enter the brain and can respond to the presence of the transgene-
Fig. 2. Histological features as well as antiviral and antitumor properties of the brain in GFAP-IL12 mice. Top row: Routine stain shows the normal histology of a wild type (WT)
cerebellum in contrast to calciﬁcations in the granule cell layer (asterisks) and lymphocyte inﬁltrations in the meninges (arrows) and the parenchyma of GFAP-IL12 mice. Middle
row: Immunohistochemistry for the nucleoprotein of Borna disease virus (BDVp40) revealed strong staining in all regions of the WT cerebellum while the cerebellum of GFAP-IL12
mice had only minor foci of immunoreactivity. Bottom row: In WT mice, GL261 glioma cells formed large tumor masses in the cerebellum which contrasted with the ﬁndings in
GFAP-IL12 mice that had smaller or no tumors.
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immunity in the CNS of the GFAP-IL12 mice is given in Fig. 3.
These ﬁndings may be highly relevant for human disease since it isFig. 3.Model for cell-mediated immunity in CNS of GFAP-IL12mice. Naive T cells in the perip
of the functional IL-12 receptor (IL-12R). These cells have increased propensity for immunos
from the astrocytes in the CNS stimulates their differentiation and the STAT4-dependent ind
effects of IFN-γ as well as further recruitment of immune cells fuels the cell-mediated immwell known that MS bouts often occur or are exacerbated after
viral or bacterial infections that would increase systemic immune
activation [74–76].hery that are exposed to stimulation from immune challenge acquire surface expression
urveillance of the CNS. The exposure of these immune cells to transgene produced IL-12
uction of IFN-γ producing T cells and NK cells. Continued stimulation by IL-12, localized
une response with destruction of neural tissues giving rise to neurological disease.
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the activation of STAT4, a key transcriptional inducer of the IFN-γ
gene [77].While not detectable in the brain fromWT or healthy GFAP-
IL12 mice, STAT4 is present in the brain of diseased GFAP-IL12 mice
and localizes to the inﬁltrating T cells [78]. This restricted localization
of STAT4 further underscores the point that the effects of IL-12 are
primarily directed at the immune cells that enter the CNS rather
than neural cells. STAT1 is another member of the STAT family whose
expression is increased dramatically in the brain of diseased GFAP-
IL12 mice. However, in contrast to STAT4, STAT1 is localized
predominantly to various neural cells including astrocytes, neurons,
and oligodendrocytes and at much lower levels in the inﬁltrating
immune cells [78]. As discussed further below, STAT1 is a crucial
transcriptional mediator in IFN-γ-regulated gene expression. The
changes in STAT1 that occur in the brain of the GFAP-IL12 mice
therefore reﬂect the presence and actions of IFN-γ in the brain of
these animals. The strength and duration of the cellular response
to IFN-γ are regulated negatively by the physiological feedback
inhibitors suppressor of cytokine signaling (SOCS) 1 and SOCS3
[79,80]. The action of these SOCS is to reduce the levels of activated
STAT1, thus dampening down IFN-γ signaling and reducing the
cellular response to this cytokine. The expression of both SOCS1 and
SOCS3 is induced in the brain of diseased GFAP-IL12 mice and, like
STAT4, localized predominantly to the inﬁltrating mononuclear cells
[78]. The restricted localization of these SOCS in the brain during the
cellular immune response in the GFAP-IL12 mice helps to explain the
observation that the levels of STAT1 are much lower in the inﬁltrating
mononuclear cell population versus the neural cells. These ﬁndings
also suggest that the response of the neural cells to IFN-γ may be
exaggerated due to less robust negative feedback control mediated
by SOCS1 and SOCS3. Similar temporal and spatial regulation of
the expression of these different STAT and SOCS genes is found in
the brain of mice with MOG-induced–EAE [78]. This indicates that
common regulatory processes likely modulate the cellular response in
the CNS in the GFAP-IL12 mice and in MOG–EAE. The interaction
between the positive (STAT) and negative (SOCS) signaling circuits
and their distinct cellular locations no doubt play a deﬁning role in
coordinating the actions of IL-12 and IFN-γ during the pathogenesis of
cell-mediated immune responses in the CNS.
Borna disease virus (BDV) is a neurotropic, noncytolytic negative
strand RNA virus that leads to encephalitis in horses, sheep, and other
animals (reviewed in [81]). Whether BDV induces disease in humans
has been the cause of hot debate. Amousemodel for Borna disease has
been established [82]. Neonatal mice on a H2Kk genetic background
are susceptible to BDVwhile mice on a H2Kb background (e.g., C57BL/
6 mice) are largely resistant. The induction of disease in mice depends
on the recognition of the TELEISSI epitope of the BDVp40 nucleopro-
tein [83]. Infection of neonatal GFAP-IL12 mice that are on a H2Kb/s
genetic background causes an earlier onset and a much higher
incidence of the disorder that develops spontaneously in these mice,
while WT mice on this background do not exhibit adverse effects
[84]. In the CNS of BDV-infected GFAP-IL12 mice, there is strong
upregulation of chemokine genes such as CXCL10, CCL5, and CCL6 as
well as IFN-γ, TNF, and NOS-2 genes. Most importantly, transgene
expressing mice show a signiﬁcant, IL-12 dose-dependent reduction
of BDV in the brain (Fig. 2) [84]. This effect is reproduced in vitro in
cerebellar slice cultures by IFN-γ but not by IL-12 [85]. In all, these
studies show that IL-12 can drive an otherwise ineffective antiviral T
cell response in the CNS and from which IFN-γ directly inhibits
viral replication and/or spread. Furthermore, in GFAP-IL12 mice
bearing the H2Kk haplotype, BDVp40-speciﬁc T cells are found
almost exclusively in the areas of IL-12 expression although other
CNS areas contain larger amounts of virus [68]. Thus, transgenic
expression of IL-12 in one part of the CNS seems to act as kind of
a lymphocyte sink to prevent other areas of the CNS that lack IL-12
from being inﬁltrated with antiviral T cells.The speciﬁc interaction between BDV infection and transgenic
production of IL-12 in the CNS was further scrutinized in GFAP-IL12
mice deﬁcient for either IFN-γ or RAG2 [68]. While BDV infection does
not lead to clinical disease in RAG2−/− GFAP-IL12 mice, all IFN-γ−/−
GFAP-IL12 animals develop disease symptoms, although at a later
time point as compared with GFAP-IL12 mice with functional IFN-γ
genes. GFAP-IL12 mice lacking IFN-γ show no reduction of BDVp40
RNA and no induction of NOS-2 RNA in the cerebellum thereby
conﬁrming the crucial role of IFN-γ in inhibiting BDV replication.
Upon BDV infection, additional proinﬂammatory factors such as
chemokines (e.g., CXCL10) are upregulated that under the inﬂuence of
IL-12 may induce immune pathology in the absence of IFN-γ. Thus,
while IL-12 induces inﬂammatory CNS disease predominantly via IFN-
γ induction, in the absence of this factor, different pathways are
possible. One possibility here is that BDV infection in the GFAP-IL12
mice induces type I IFN production in the brain. This would then
explain the observed increase in the chemokine CXCL10 which is
known to be induced by type I IFNs.
The antitumor activity of cerebral IL-12 was examined using
glioma cells of the GL261 line implanted in the cerebellum of GFAP-
IL12 mice. Cerebral production of IL-12 mediates strong rejection of
GL261 cells with transgenic mice exhibiting smaller tumors (Fig. 2)
and better health [86]. The rejection of tumor cells in GFAP-IL12 mice
is mediated predominantly by CD8+ T cells. Surprisingly, GFAP-IL12
mice lacking IFN-γ show a similar capability for tumor rejection [86].
This ﬁnding is unexpected since a number of reports demonstrate that
IFN-γ is an important mediator of IL-12 induced antitumor effects
[87–90]. IFN-γ acts against neoplasms on several levels including
antiangiogenic effects and induction of NOS-2 that has cytotoxic
effects on glioma cells in vitro [89]. However, IFN-γ can have opposite
effects as well, since it can upregulate the immunosuppressive factor
B7-H1 on glioma cells [91]. The actions of IFN-γ in the context of
tumor immunity are not unilateral and more experiments are needed
to clarify this issue.
5. Interferons — antiviral cytokines that also induce neurological
disease
Interferons (IFNs) are a heterogeneous group of cytokines that
have multiple functions both in the innate and adaptive immune
systems (reviewed in [92,93]). Based on biological properties, the IFNs
are grouped into three families. The type I IFN family contains
multiple members, including several IFN-α isoforms and a single IFN-
β that are produced by various cell types. Deﬁciencies in type I IFN
function render humans [94,95] and mice [96,97] highly susceptible
to viral infection highlighting their integral role in host defense. In
contrast, IFN-γ is the only member of the type II IFN family. IFN-γ
production occursmainly in activated T- and NK cells and is important
in type 1 cell-mediated immunity (for reviews, see [98,99]). The type
III IFN family has been recently classiﬁed (reviews in [100]) and
contains IFN-λ1, -λ2, and λ3 (interleukin (IL)-29, -28A, and -28B,
respectively). Although not as well characterized as the type I and
type II IFNs, the biological activities of type III IFNs appear to be similar
to the type I IFNs.
All members of the type I IFN family bind to a common receptor,
termed IFNAR, whereas IFN-γ and the type III IFNs bind to their own
unique receptors, termed IFNGR and IL28RA, respectively [92].
Binding of type I IFNs to the IFNAR activates receptor-associated
tyrosine kinases that belong to the Janus-kinase family (Tyk2 and
Jak1) [92,101,102]. These JAKs phosphorylate tyrosine residues in the
cytoplasmic domain of the IFNAR as well as tyrosine residues of the
latent cytoplasmic transcription factors signal transducer and acti-
vator of transcription (STAT) 1 and STAT2. Activated STAT1 and STAT2
form heterodimers that translocate to the nucleus and interact with
a third molecule, interferon regulatory factor 9 (IRF9), forming a
heterotrimeric complex. This complex, called interferon-stimulated
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elements (ISREs) found in the promoter region of type I IFN-regulated
genes. In contrast, IFN-γ binding to the IFNGR activates JAK1 and JAK2
which phosphorylate STAT1. Phosphorylated STAT1 forms homo-
dimers which translocate to the nucleus and bind to gamma activated
sequences (GAS) found in the promoter region of type II IFN-regulated
genes [98]. Similar to the type I IFNs, activation of the IL28RA induces
the formation of the ISGF3 complex [100].
5.1. IFN-α
Detection of microorganisms by host pathogen-associated mole-
cular pattern recognition receptors such as the TLRs or RIG-I induces
the production of the type I IFNs IFN-α and IFN-β [103]. In the CNS,
resident cells such as astrocytes and microglia can secrete consider-
able amounts of type I IFNs [104,105]. Activation of IFNAR-coupled
signaling pathways regulates the transcription of several hundred
type I IFN-regulated genes resulting in a plethora of biological effects
[106]. Beside being antiviral, type I IFNs inﬂuence metabolism, cell
growth and differentiation, immune function, and tumor develop-
ment [92,107]. On the other hand, type I IFNs are also implicated in
the pathogenesis of several neurological diseases such as HAD and the
genetic disorders Aicardi–Goutières syndrome (AGS) and Cree
encephalitis [108–110]. Intrathecal production of type I IFNs is linked
to neuropsychiatric symptoms in patientswith chronic viral infections
or systemic lupus erythematosus [111–114]. While being a very
effective drug in the therapy of some chronic viral infections and
malignant tumors [115], treatment with type I IFNs often has severe
neurological side effects and may result in death [116,117]. Therefore,
a thorough understanding of the biological actions of this cytokine
and of the signal pathways responsible for these actions is of
considerable importance.
The impact of type I IFN production in the CNS has been studied in
transgenic mice that produce IFN-α1 under the control of the GFAP
promoter (GIFN mice) [118,119]. The GIFN mice express the
transgene predominantly in the medial–ventral forebrain and the
cerebellum causing a dose-dependent neurological disorder. One
GIFN transgenic line with moderate levels of IFN-α develops
progressive disease with seizures, weight loss, and premature death.
A second GIFN line, which produces much lower levels of IFN-α in the
brain, exhibits behavioral changes and learning deﬁcits [119]. Aged
mice of this line develop milder signs of a neurological disease. The
morphological correlates of this disease are foci of necrosis with
prominent calciﬁcation in the medial–ventral forebrain and cerebel-
lum that lead to a loss of neurons. Surrounding the necrotic foci,
activation of blood vessels, reactive astrogliosis, and inﬁltrating
leukocytes are conspicuous. These cellular changes are accompanied
by the markedly increased expression of characteristic type I IFN-
regulated genes such as 2′5′ oligoadenylate synthetase (2′5′OAS),
protein kinase R (PKR), and MHC class I, indicating that the observed
effects are linked to IFN-α [118]. Importantly, the characteristic
calciﬁcation in the deep white matter and basal ganglia of GIFN mice
bear a striking resemblance to the changes seen in the brains of
children with AGS, congenital HIV infection, or CVE [108,120–122].
The hippocampus is particularly vulnerable to HIV [123] and infection
of the CNS causes neurodegenerative changes in the hippocampus
that likely contribute to the symptoms of progressive cognitive
impairment and cerebral seizures [124]. Similar symptoms are also
observed as side effects of IFN-α therapy [117] or in patients with AGS
[125] indicating a potential link between chronic viral infection and
increased production of this cytokine in the brain. Electrophysiologi-
cal studies in GIFN mice show there is neuronal hyperexcitability and
dysfunction in the hippocampus which further supports this idea
[119]. The morphological and functional changes may also form the
basis for the seizures seen in GIFN mice with higher levels of
transgene-encoded IFN-α. In summary, the chronic production of IFN-α in the CNS of GIFN mice leads to pathological changes and clinical
symptoms that resemble ﬁndings from human diseases that coincide
with increased cerebral production of IFN-α such as viral infections or
certain genetic and autoimmune disorders such as AGS and SLE
encephalopathy, respectively.
Although IFN-α has potent antiviral properties, its clinical use in
humans as a drug for viral encephalitis has been limited to a few cases
of West Nile virus (WNV) encephalitis [126] and HIV-associated
progressive multifocal leukoencephalopathy (PML) [127,128]. In
these cases, IFN-α therapy was associated with increased recovery
of neurologic function and prolonged survival. Concordantly, several
studies show that GIFN mice are protected from infection with a
variety of different classes of virus including lymphocytic choriome-
ningitis virus (LCMV), Herpes simplex virus (HSV), and BDV
[118,129,130]. In all cases, protection is associated with a signiﬁcant
decrease in viral replication and spread throughout the CNS and
reduced immune pathology. These results demonstrate the important
role of IFN-α in antiviral host defense in the brain. In addition, the
studies in the GIFN mice highlight the role of IFN-α as a “double-
edged sword”. While protecting against detrimental viral infections,
chronic expression of IFN-α in the CNS also causes inﬂammation,
calciﬁcation, and a destructive neurological disease.
As outlined above, formation of the ISGF3 transcription factor
complex is central in the cellular responses to type I IFNs. But it
has been shown that other, so-called noncanonical pathways and
transcription factors are activated as well [131]. To elucidate the role
of the various pathways in the context of type I IFN actions in the CNS,
GIFN mice have been interbred with mice deﬁcient for the canonical
signaling molecules STAT1 [132] or STAT2 [133]. Surprisingly, GIFN
mice with low IFN-α production in the brain lacking either of these
canonical signaling molecules develop severe neurological disease
with an early-onset age. These ﬁndings clearly demonstrate that
noncanonical type I IFN signaling occurs in the CNS. Moreover a
balance between ISGF3-dependent and ISGF3-independent signaling
is critical to minimize the adverse effects of type I IFNs. Lack of
either STAT1 or STAT2 in the GIFN mice has distinct clinical and
pathophysiological effects pointing to the existence of multiple
noncanonical signaling pathways.
In STAT1-deﬁcient GIFN mice, extensive tissue destruction
and inﬂammatory lesions and higher expression of proinﬂamma-
tory cytokines (e.g., TNF, IL-1α, IL-β, IFN-γ) are seen in the CNS.
Expectedly, expression of characteristic type I IFN-regulated genes
(e.g., 2′5′OAS, PKR, MHC I) was also diminished mice. This shows that
noncanonical signaling pathways activated by type I IFNs can
contribute to disease highlighting the fact that an equilibrium of
signaling pathways is critical in programming the biological actions of
the type I IFNs. Dysregulation in these signaling pathways may occur
for example, following viral infection [134] and could enhance the
pathophysiological actions of the type I IFNs.
In contrast to GIFNmice lacking STAT1, STAT2-deﬁcient GIFNmice
develop primitive neuroectodermal tumors in the cerebellum and die
around 1 month of age [133]. The tumors are reminiscent of
medulloblastomas which are found mainly in children where they
are the most common of the malignant pediatric brain tumors [135].
Dysregulation of the Sonic Hedgehog (Shh) signaling pathway is
implicated in the pathogenesis of a subgroup of medulloblastomas in
children [136,137]. Both Shh and the downstream transcriptional
factor Gli1 are aberrantly expressed in the cerebellar granule neurons
and tumor cells in STAT2-deﬁcient GIFN mice. It is likely that chronic
activation of this developmental pathway in progenitor granule
neurons accounts for the abnormal proliferation and eventual
neoplastic transformation of these cells seen in the brain of the
STAT2-deﬁcient GIFN mice [133]. In these mice, concomitant with
tumor development there is a pronounced cell-mediated immune
response that results in the localized production of IFN-γ. Interest-
ingly, IFN-γ, but not IFN-α, induces the STAT1-dependent expression
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neurons [133]. Studies in transgenicmicewith inducible expression of
IFN-γ in the CNS (see below) conﬁrm the important role of IFN-γ as a
mediator of Shh gene expression. Thus, the immune system via IFN-γ
is capable of markedly altering the function of a key developmental
pathway in the brain resulting in tumorigenesis.
In summary, IFN receptor signaling is clearly complex, involving
the coexistence of multiple JAK/STAT as well as alternative pathways.
The balance in the activity of these pathways ultimately determines
the repertoire of CNS responses regulated by IFN-α. Primary signaling
occurs via the ISGF3 pathway leading to the induction of ISRE-
dependent genes that favor protective processes in the CNS (Fig. 4).
However, a reduction or loss of signaling via the primary ISGF3
pathway results in a shift to favor the activation of noncanonical
signaling pathways. The altered signaling resulting from this shift
accentuates more destructive processes and increased severity of
neurological disease mediated by IFN-α.
5.2. IFN-γ
Similar to the type I IFNs, IFN-γ is a plurifunctional cytokine.
Originally described as a potent antiviral cytokine like the type I IFNs,
IFN-γ exerts a wide range of effects within and outside the immune
system (reviewed in [98]). In the mature CNS, consistent with its
restricted production to activated T and NK cells, IFN-γ is not present
at detectable levels normally but is found in a variety of immunoin-
ﬂammatory states such as following infection or in autoimmune
diseases such as MS. Within the CNS there is considerable evidence
that IFN-γ has a wide range of actions that affects all the major neural
cells (reviewed in [138,139]). Such actions include alterations in the
growth and differentiation of neurons and oligodendrocytes as well as
modulation of the function of microglia and astrocytes.
Several groups independently developed IFN-γ transgenic mice to
study the impact of this cytokine on the CNS. In these studies, themice
produced IFN-γ constitutively either under the control of the MBP
promoter in oligodendrocytes [140,141] or under the control of the
GFAP promoter in astrocytes [142]. Progressive ataxia, shivering, andFig. 4. Model for canonical and noncanonical type I IFN signaling in glial cells. In WT
cells, IFN-α induces the formation of the ISGF3 complex that consists of STAT1:STAT2:
IRF9 trimers. This results in increased expression of predominantly ISRE-regulated
genes that are more protective. In the absence of STAT1 or STAT2, alternative signaling
complexes are activated resulting in increased expression from GAS-, IRE- and possibly
other response element-regulated genes that lead to more pathogenic effects of type I
IFNs in the murine CNS.tremors resulting in premature death are characteristic features of
most IFN-γ transgenic mice independent of the promoter used. The
disease is accompanied by extensive hypo- and demyelination in the
CNS [140–142]. In addition, foamy macrophages containing myelin
fragments suggestive of active demyelination are present in the CNS
in some IFN-γ transgenic mice [141]. However, in general, these
different IFN-γ transgenic mice exhibit little or only minor leukocyte
accumulation in the CNS. This suggests that developing myelin-
producing oligodendrocytes are highly sensitive to IFN-γ. In support
of this are data showing that overexpression of SOCS1 in IFN-γ
transgenic mice ameliorates the loss of oligodendrocytes and
hypomyelination [143]. This highlights the functional signiﬁcance of
negative feedback signaling in down regulating IFN-γ actions. In the
case of oligodendrocytes, SOCS1 levels seem to be insufﬁcient under
normal circumstances to prevent the harmful effects of IFN-γ.
The mechanism by which IFN-γ can cause damage to oligoden-
drocytes in these transgenic mice may involve endoplasmic
reticulum (ER) stress and apoptosis [143–145]. Phosphorylation of
eIF-2α by the pancreatic ER kinase (PERK), a process termed
integrated stress response (ISR), is an important protective
mechanism from ER stress and has been shown to occur in a
number of disorders of myelinating cells [146]. However, severe or
prolonged ER stress leads to the activation of apoptosis and the
eventual death of the cell. Decreased activity of the PERK-eIF2a
pathway via PERK inactivation exacerbates IFN-γ-induced oligoden-
drocyte apoptosis and hypomyelination [145]. In addition to the
harmful effects of IFN-γ on developing oligodendrocytes and axonal
myelination, IFN-γ also inhibits remyelination in mice with EAE or
following cuprizone-induced demyelination [147]. Similar to the
observations in developing oligodendrocytes, evidence indicates
that this was associated with increased ER stress.
Another line of transgenic mice with IFN-γ production by
oligodendrocytes have increased demyelination after induction of
EAE [148]. These mice have no spontaneous phenotype but develop a
chronic progressive form of EAE with extensive demyelination,
whereas nontransgenic mice had an acute self-limiting form of the
disease. However, the ﬁndings of this study contrast with those from
two studies that found IFN-γ protects oligodendrocytes from
immune-induced damage and the CNS from subsequent demyelina-
tion in EAE [149,150]. Surprisingly, the protective effect of IFN-γ in
EAE was attributed to modest ER stress induced by IFN-γ in mature
oligodendrocytes conferring resistance to EAE-induced demyelina-
tion, axonal damage, and oligodendrocyte loss [150]. The results of
these EAE studies in the IFN-γ transgenic mice seemingly contradict
previous ﬁndings by this group discussed above, showing that ER
stress induced by IFN-γ in myelinating or remyelinating oligoden-
drocytes is detrimental causing oligodendrocyte apoptosis andmyelin
abnormalities. To resolve these differences, the authors propose that
the outcomes of ER stress induced by IFN-γ in oligodendrocytes are
determined by the developmental status of the cells. Actively
myelinating oligodendrocytes respond with cell death to ER stress,
while in mature oligodendrocytes, this reaction is protective. The
exact molecular mechanisms underlying this differential outcome to
ER stress are not known. However, in contrast to mature cells,
developing oligodendrocytes that are in the process of (re-)myelinat-
ing axons require an immense amount of newly synthesized proteins.
It is conceivable that even a short-term disruption of this process has
severe consequences on various critical cellular processes resulting in
apoptosis and cell death.
A developmental disorder has also been described in transgenic
mice with IFN-γ production by either oligodendrocytes [140] or
astrocytes [142] consisting of cerebellar dysplasia with the persis-
tence and gross hyperplasia of the external granule layer. More
recently, conditional induction of perinatal IFN-γ production by
astrocytes in the CNS recapitulated these developmental abnormal-
ities and promoted the development of medulloblastoma [151]. A
912 I.L. Campbell et al. / Biochimica et Biophysica Acta 1802 (2010) 903–917direct causal relationship between IFN-γ production and the activa-
tion of the Shh signaling pathway in granular neuron cells was
established [151,152]. As discussed above, IFN-γ-mediated activation
of the Shh signaling pathway in granular neuron cells leads to the
autocrine stimulation of these cells, inappropriate EGL hyperplasia,
and formation of medulloblastoma.
6. TGF-β is a major player in the development of hydrocephalus
and cerebral amyloidosis
The cytokine TGF-βwas originally described as a growth factor for
ﬁbroblasts. Since then, numerous studies have demonstrated a wide
range of additional functions indicating that TGF-β is produced by
most cell types and is involved in a multitude of biological processes
including embryogenesis, carcinogenesis, cell growth, cell differentia-
tion, and activation and immunoregulation (reviewed in [153–155]).
Not surprisingly, TGF-β deﬁciency in mice is either embryonically or
perinatally lethal. In mammals, three isoforms exist (TGF-β1, -β2, and
-β3) that are produced as propeptides and activated involving a
multistep cascade. The propeptide is cleaved into mature TGF-β and
the latency-associated protein (LAP) that form noncovalently linked
complexes. Following secretion, complexed TGF-β must be liberated
by a factor termed TGF-β activator (TA) in order to be able to bind to
its receptor. TGF-β and TA can originate from different cell types
allowing for a sophisticated regulation of TGF-β activity. Activated
TGF-β is recognized by three different TGF-β receptors (TGF-βR) that
cooperate in the regulation of TGF-β signaling [155]. The type III TGF-
βR exists as a soluble and membrane-bound form. The soluble form
acts as a decoy receptor that intercepts TGF-β before it can bind to a
membrane-bound receptor while the membrane-bound type III TGF-
βR binds active TGF-β and passes it to the type II TGF-βR. Complexes
consisting of the type II and type I TGF-βR (also called ALK-5) form an
active receptor complex that functions as a serine–threonine kinase.
In the primary TGF-β signaling pathway, phosphorylated receptor-
associated Smad2 and Smad3 form transcriptionally active complexes
with Smad4 that bind to Smad DNA-binding elements (SBEs) to
modulate transcription of TGF-β-regulated genes. TGF-β has also been
shown to stimulate the type I receptor ALK1 activating Smad1. In
addition, several Smad-independent signaling pathways including the
MAPK or the PI3K kinase pathways contribute to the biological effects
of TGF-β [156,157].
The effects of TGF-β on the CNS are multifaceted and poorly
understood (reviewed in [158,159]). Most neural cell types can
produce TGF-β and low levels are detectable in the CSF of healthy
humans. Expression of TGF-β2 and TGF-β3 is predominantly con-
trolled by hormonal and developmental signals indicating a more
important role in physiological processes such as CNS development. In
contrast, TGF-β1 expression is increased in response to various danger
signals such as trauma, infection, inﬂammation, or neurodegenera-
tion. Following traumatic injury, increased production of TGF-β1 is
observed predominantly in astrocytes and microglia. Elevated levels
of TGF-β1 in the CNS or CSF are also observed in HAD, AD, and in MS.
To study the effects of TGF-β on the CNS in health and disease two
groups independently reported the generation of transgenic mice
with astrocyte-directed production of TGF-β1 under the control of the
GFAP promoter [160,161]. Both studies report that transgenic mice
with higher TGF-β1 production develop a severe spontaneous
neurological disease with a communicating non-obstructive hydro-
cephalus. Furthermore, while transgenic mice with low levels of TGF-
β1 do not develop a spontaneous disease, traumatic CNS injury also
induces the development of hydrocephalus in these mice [161].
Intraventricular injection of TGF-β1 can induce hydrocephalus in mice
[162] and high TGF-β1 levels in the CSF of patients with intracranial
bleeding are associated with increased risk to develop a hydrocepha-
lus [163]. Taken together, these ﬁndings clearly indicate that excessive
TGF-β1 production in the CNS is involved in the development ofhydrocephalus. In addition to hydrocephalus, Galbreath et al. [160]
describe a hypoplasia of the cerebellum with a reduced number of
cerebellar foliae in spontaneously diseased TGF-β1 transgenic mice.
These ﬁndings indicate that TGF-β1 might act negatively on neural
and/or neuronal cell proliferation. In line with this, in vitro studies
show that TGF-β1 inhibits the proliferation of neuronal progenitor
cells and aged TGF-β1 transgenic mice show reduced adult neurogen-
esis in the hippocampus [164]. Interestingly, no differences in the total
number of neurons in the hippocampus of adult wild type and TGF-β1
transgenic mice are seen, suggesting that TGF-β1 may also act as a
survival factor for mature neurons. This possibility is strengthened by
the observations that transgenic mice with low levels of CNS TGF-β1
[165] or mice with adenoviral induced production of TGF-β1 in the
CNS [166] are more resistant to kainic acid induced neuronal
excitotoxicity. Likewise, hypoxia-induced damage and infarction
size are signiﬁcantly reduced in mice with adenoviral expression of
TGF-β1 in the CNS [167]. Conversely, 3-week-old TFG-β1-deﬁcient
mice display reduced synaptogenesis in the cortex and hippocampus
and increased neuronal loss in response to kainic acid [165]. Thus,
TGF-β1 seemingly has both negative as well as positive roles in
neuronal differentiation and neuroprotection. While the molecular
mechanisms of TGF-β1-mediated neuroprotection are unclear, several
studies have demonstrated that TGF-β1 decreases pro-apoptotic
pathways and induces production of antiapoptotic proteins
[168,169]. Furthermore, TGF-β has been shown to enhance neuronal
survival mediated by neurotrophins and nerve growth factor [170]
and to positively regulate expression of laminin which promotes
neurite outgrowth [161,165].
Transgenic mice with low levels of TGF-β1 in the CNS do not
develop spontaneous hydrocephalus but show signs of a progressive
cerebral angiopathy. Electron microscopy reveals that these TGF-β1
transgenic mice have a thickening of the vascular basal lamina and
morphologic changes to endothelial cells [171]. These changes result
in a focally reduced blood perfusion rate [172]. Importantly, these
alterations precede the deposition of amyloid in the vessel walls
[171]. The deposition of amyloid in vessel walls is of special interest
as it is also a characteristic feature of cerebral amyloid angiopathy
(CAA) in humans [173]. CAA is a common cause of spontaneous
cerebral hemorrhage in aged humans and it is associated with AD
[174]. Patients with AD show elevated levels of TGF-β in the
affected brain areas [175]. Furthermore, TGF-β1 is more strongly
expressed around cerebral vessels in AD patients with CAA than in
AD patients without CAA, further supporting a role for TGF-β in CAA
[176]. Interestingly, levels for the type II TGF-βR are reduced in the
CNS of patients with AD [177] suggesting there may be reduced
responsiveness to this cytokine. Thus, it might well be that the
increased TGF-β levels in AD are, in part, the consequence of
reduced signaling due to decrease of the receptor. In contrast to the
CNS of patients with AD, TGF-β1 transgenic mice do not develop
parenchymatous amyloid plaque formation in the brain [171,176].
Interestingly, while hAPP transgenic mice develop extensive
amyloid plaque pathology, plaques are absent in hAPP-TGF-β1
transgenic mice. However, the double-transgenic mice show an
accelerated and enhanced vascular amyloid deposition compared
with TGF-β1 single-transgenic mice [176,178]. These ﬁndings
suggest TGF-β1 mediates amyloid clearance from the brain but
conversely promotes amyloid deposition in vessel walls, thus
contributing to the development of CAA. The mechanism respon-
sible for the clearance of the amyloid plaques from hAPP-TGF-β1
transgenic mice appears to involve an innate immune response with
activation of plaque associated microglia and complement-mediated
phagocytosis of amyloid [178,179].
Increased numbers of T cells occur in the parenchyma of TGF-β1
and hAPP-TGF-β1 double-transgenic mice following immunization
with amyloid-beta peptide [180] showing that local cerebral expres-
sion of TGF-β1 increases the sensitivity of the CNS towards
Table 1
Comparative features of some CNS cytokine transgenic mouse modelsa.
Promoter/target cell Clinical features Cellular changes Inﬁltrating
leukocytes
Human disease correlates





















cellNB cellNCD8+ T cell
Multiple sclerosis, stroke,
bacterial meningoencephalitis








IFN-α GFAP/astrocyte Learning deﬁcits, reduced activity,
weight loss, seizures, premature
death
Encephalitis, gliosis, multifocal
calcifying necrosis with neuronal
loss
Mild. CD4+≫CD8+ T cellNB
cellNmacrophage
Aicardi–Goutières syndrome,









cerebellar hyperplasia, and tumor
Mild. MacrophageNT cell Multiple sclerosis (MS)
Medulloblastoma
TGF-β1 GFAP/astrocyte Moribund, premature death in
high TGF-β-expressing mice
Hydrocephalus (high expression),
amyloid angiopathy, blood vessel
ﬁbrosis, gliosis, neuroprotection,
reduced neurogenesis
Mild. T cell Cerebral amyloid angiopathy,
Alzheimer's disease
a Citations not included, refer to text for details.
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TGF-β1 transgenic mice develop more severe EAE with more
extensive leukocyte inﬁltrates in the spinal cord and brain
[181,182]. Furthermore, TGF-β is expressed in the CNS of wild type
mice several days before onset of EAE symptoms or inﬁltration by
lymphocytes and inhibition of cerebral TGF-β signaling ameliorates
EAE symptoms and reduces lymphocyte inﬁltration into the CNS
[181]. Importantly, this has no effect on T cell populations in the
spleen or CNS including Th17 and Th1 CD4+ T cells. These results
indicate that cerebral production of TGF-β1 in the mouse CNS induces
a state that makes the CNS more susceptible to peripheral immune
responses. Localized expression of TGF-β occurs in plaque lesions of
MS patients, suggesting that TGF-β may have a similar role in MS
[183].
Importantly, the dual nature of TGF-β1 action is also illustrated by
the EAE disease model where peripheral administration of TGF-β
inhibits the development of EAE [184–186], indicating that the
anatomical location of TGF-β release is crucial for the outcome of its
biological effects. As noted above, TGF-β in combination with IL-6
plays an important role in the differentiation of proinﬂammatory,
autoreactive Th17 CD4+ T cells that are crucial in EAE development.
Mice with T cells that are unresponsive to TGF-β do not produce Th17
T cells and are resistant to EAE induction [44], whereas mice with
increased production of TGF-β1 in T cells develop more severe EAE
[42]. These ﬁndings clearly distinguish the systemic from the localized
CNS effects of TGF-β and have important implications for any
attempts at therapeutic modulation of this cytokine in the treatment
of diseases such as MS.
7. Concluding comments
Targeting the expression of individual cytokine genes to the
CNS in transgenic mice has provided a powerful approach to the
investigation of complex cellular responses at a localized level. The
results of studies in these transgenic mice have greatly increased
knowledge of the fundamental mechanisms in the brain that are
linked to a variety of neurological disorders that involve cytokines
(summarized in Table 1). Importantly, the cerebral production of
the various cytokines discussed above induce distinct clinical,
behavioral, physiological, cellular, and molecular phenotypes, and
while there are some overlapping features, the differences are more
prominent reﬂecting the unique actions of each cytokine. In relationto the relevance of these models to our understanding of the role of
cytokines in human disease, it should be borne in mind that like all
animal models, the CNS cytokine transgenic mice discussed in this
review have limitations. In this regard, the nature of the transgene-
encoded cytokine production itself being constitutive and present
throughout the life of the animal does not replicate the more
episodic production of cytokines found in various neurological
disease states in humans. Nevertheless, as highlighted here, there
are remarkable overlaps between the structural and functional
changes observed in the CNS of the different cytokine transgenic
mice and those found in various human neurodegenerative and
demyelinating diseases. Such overlap reinforces the importance
of these transgenic models for studying cytokine-mediated CNS
inﬂammation and disease and solidiﬁes the concept that locally
produced cytokines have a primary role as direct effectors in the
pathogenesis of CNS disease.
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